Horumarka Daaweynta Khadka Koowaad ee Dadka Waaweyn ee B-ALL: Dib u eegis Dhammaystiran oo ka socota The Lancet Hematology

Dib-u-eegis hal-abuur leh oo lagu daabacay gudaha Daaweynta Dhiigga ee Lancet, khubaradu waxay faahfaahin ka bixiyeen horumarradii ugu dambeeyay ee laga sameeyay daaweynta safka hore ee dadka waaweyn ee B-cell Lymphoblastic Leukemia (B-ALL), iyagoo xoogga saaraya muhiimadda ay leedahay istaraatiijiyadaha daaweynta shaqsiyeed iyo isku-darka daaweynta difaaca jirka ee cusub. Tobankii sano ee la soo dhaafay, daaweynta dadka waaweyn ee cusub ee la ogaaday ee B-ALL waxay samaysay horumarro muhiim ah sababtoo ah faham qoto dheer oo ku saabsan bayoolajiga cudurka, horumarinta hababka tirada ugu yar ee cudurrada harsan (MRD), iyo ku darista daawooyinka carruurta dhiirigeliya (PIR) si loo helo natiijooyin wanaagsan.

Dib-u-eegistu waxay hoosta ka xariiqaysaa in inkastoo bukaanada qaangaarka ah ee B-ALL ay weli la kulmaan caqabado la xiriira daaweynta oo aan shaqeyn iyo heerarka dhimashada oo sarreeya marka loo eego carruurta, haddana dhowr istaraatiijiyadood oo muhiim ah ayaa hagaajinaya saadaasha. Bukaannada da'da yar, isticmaalka daawooyinka carruurta lagu dhiirigeliyo ayaa ka waxtar badan daaweynta dadka waaweyn ee dhaqameed, iyadoo heerarka badbaadada muddada dheer ay gaarayaan ilaa 78%. In kasta oo faa'iidada daawayntani ay hoos u dhacdo marka da'da la gaaro, haddana habkani wali wuxuu bixiyaa horumarro muhiim ah, gaar ahaan marka lagu daro daaweynta casriga ah ee la beegsanayo sida tyrosine kinase inhibitors (TKI) ee Philadelphia chromosome-positive (Ph+) B-ALL.

Intaa waxaa dheer, ku darista daawooyinka difaaca jirka sida antibodies-ka monoclonal-ka ee ka hortagga CD20 (tusaale ahaan, Belantamab Mafodotin iyo Inotuzumab Ozogamicin) ee hababka daaweynta ee safka hore waxay muujisay ballanqaad lagu yareynayo sunta la xiriirta kiimoterabi iyo kor u qaadista heerarka jawaabta. Daraasaduhu waxay muujiyeen in wakiiladan, marka lala isticmaalo kiimoterabi-ga caadiga ah, ay si weyn u kordhiyaan heerarka cafinta, gaar ahaan noocyada hidde-sideyaasha khatarta sare leh ee B-ALL.

Bukaannada da'da ah (>60 sano), waa cusub oo daaweyn ah ayaa soo ifbaxday iyadoo la adeegsanayo daawooyinka xoogga yar oo ay weheliso daawooyinka difaaca jirka. Hababkani waxay higsanayaan inay yareeyaan culeyska kiimoterabiga, iyagoo bixinaya ikhtiyaar ammaan ah oo loo dulqaadan karo kooxdan nugul. Daraasadaha kiliinikada ayaa si firfircoon u sahaminaya is-dhexgalka ugu habboon ee daaweyntan, oo ay ku jiraan isticmaalka daaweynta unugyada CAR-T iyo wakiilada la beegsanayo, si loo sii wanaajiyo natiijooyinka.

Dib-u-eegistu waxay ku soo gabagabaynaysaa in inkastoo horumar badan laga sameeyay hagaajinta daaweynta safka hore ee dadka waaweyn ee B-ALL, cilmi-baarista socota iyo tijaabooyinka caafimaad ayaa muhiim u ah wax ka qabashada farqiga daaweynta, gaar ahaan bukaanada khatarta sare leh iyo kuwa waayeelka ah. Qorshayaasha daaweynta ee shaqsiyeed ee ku salaysan muuqaalka hidde-sidaha iyo molecular-ka, iyo sidoo kale horumarinta sii socota ee daaweynta difaaca jirka, waxay bixiyaan rajo natiijooyin ka wanaagsan mustaqbalka.

Falanqayntan dhammaystiran ee daaweynta B-ALL waxay calaamad u tahay marxalad muhiim ah oo ka mid ah dagaalka socda ee ka dhanka ah kansarkan adag ee dhiigga ku dhaca, taasoo rajo cusub u keenaysa bukaanada adduunka oo dhan.